Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 September 2018 Photo Hanno Otto
Consecutive international win for OSM Camerata
The OSM Camerata is once again a winner, sharing the first prize in the Ictus International Music Competition with the Oklahoma State University.

If Einstein’s string theory had a musical undertone, one would think it is because of the sweet melodies of the Odeion School of Music Cameratas’ (OSMC) violins and cellos. It should therefore come as no surprise that OSMC won the 2018 International Ictus Music Competition, again. The ensemble has been paving the way to numerous successes since its inception in 2012.

This year, however, the OSMC is sharing the first prize with the Oklahoma State University Symphony Orchestra, under the direction of Dr Thomas Dickey. The OSMC’s competition recital for 2018 was conducted by principle conductor, Xavier Cloete. Acclaimed violist Elsabé Raath, joined the OSMC artistic team in 2017 as string clinician.

OSMC the jewel in crown

The OSMC is based at the Odeion School of Music (OSM) at the University of the Free State UFS) and was strategically founded as the OSM’s flagship ensemble with the main objective, creating a catalyst for excellence. “From a pedagogical perspective, it serves as a feasible incubator to nurture fully-rounded musicians who are thoroughly prepared for the demands of their trade as orchestral musicians, soloists and conductors,” said Marius Coetzee founder of the OSMC.

“Ms Raath also made her debut as conductor during the 2018 Ictus Music Competition where she conducted O Sacrum Convivium by Olivier Messiaen,” said Coetzee, founder of the OSMC. Elsabé was also conductor during the 2018 Ictus Music competition.

The OSMC’s concert programme for Ictus 2018 also consisted of works by Jacobus Gallus/Lance Phillip, Béla Bartók, Peteris Vasks/Keith Moss, as well as Johann Sebastian Bach.

Ictus an ideal platform


The Ictus International Music Competition is an online music competition for wind bands, orchestras and solo trumpet. It has been described by David Bilger of the Philadelphia Orchestra as “democratising music competitions”. Ictus was founded to make international music competitions more accessible though eliminating prohibitive travel costs, conference fees and visa issues. This was made possible through having the application and adjudication take place online only. 

You can listen to OMSC Ictus submissions here:

Duo Seraphim Jabobus Gallus/Lance Phillip
Romanian Folk Dances/ Román népi táncok Béla Bartók
Kekatu Dziesma (Carnival Song) Peteris Vasks/Keith Moss

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept